ZOO Digital Group plc (AIM:ZOO)
London · Delayed Price · Currency is GBP · Price in GBX 12.62
-0.63 (-4.75%)
Aug 6, 2025, 4:21 PM GMT+1
Theseus Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2016 - 2020 |
| 46.78 | 40.63 | 90.26 | 70.4 | 39.53 | 29.79 | Upgrade | |
Revenue Growth (YoY) | -22.35% | -54.99% | 28.21% | 78.12% | 32.66% | 3.38% | Upgrade |
Cost of Revenue | 33.29 | 35.17 | 56.33 | 49.56 | 25.88 | 19.71 | Upgrade |
Gross Profit | 13.49 | 5.46 | 33.93 | 20.84 | 13.64 | 10.09 | Upgrade |
Selling, General & Admin | 9.19 | 9.57 | 10.49 | 8.43 | 5.84 | - | Upgrade |
Research & Development | 0.51 | 0.51 | 0.6 | 0.28 | 0.32 | - | Upgrade |
Other Operating Expenses | 9.14 | 9.14 | 7.33 | 5.17 | 2.85 | 10.39 | Upgrade |
Operating Expenses | 24.38 | 24.76 | 25.81 | 18.46 | 12.6 | 10.64 | Upgrade |
Operating Income | -10.89 | -19.3 | 8.12 | 2.38 | 1.05 | -0.56 | Upgrade |
Interest Expense | -0.44 | -0.57 | -0.62 | -0.52 | -0.7 | -0.67 | Upgrade |
Interest & Investment Income | 0.07 | 0.21 | 0.02 | - | - | - | Upgrade |
Earnings From Equity Investments | -1.97 | -0.87 | 0.15 | - | - | - | Upgrade |
Currency Exchange Gain (Loss) | -0.05 | -0.18 | 0.2 | 0.09 | -0.46 | 0.2 | Upgrade |
Other Non Operating Income (Expenses) | - | - | - | -1.55 | -3.46 | 0.99 | Upgrade |
EBT Excluding Unusual Items | -13.28 | -20.7 | 7.86 | 0.4 | -3.57 | -0.05 | Upgrade |
Gain (Loss) on Sale of Assets | 0.26 | 0.26 | - | - | - | - | Upgrade |
Asset Writedown | - | - | - | -0.61 | - | - | Upgrade |
Pretax Income | -13.03 | -20.45 | 7.86 | -0.21 | -3.57 | -0.05 | Upgrade |
Income Tax Expense | 1.29 | 1.48 | -0.37 | -1.57 | -0.41 | -0.36 | Upgrade |
Net Income | -14.31 | -21.93 | 8.23 | 1.36 | -3.16 | 0.32 | Upgrade |
Net Income to Common | -14.31 | -21.93 | 8.23 | 1.36 | -3.16 | 0.32 | Upgrade |
Net Income Growth | - | - | 504.41% | - | - | -80.64% | Upgrade |
Shares Outstanding (Basic) | 98 | 97 | 89 | 85 | 75 | 74 | Upgrade |
Shares Outstanding (Diluted) | 98 | 97 | 96 | 94 | 75 | 81 | Upgrade |
Shares Change (YoY) | 5.40% | 1.57% | 2.24% | 25.50% | -8.15% | 0.61% | Upgrade |
EPS (Basic) | -0.15 | -0.23 | 0.09 | 0.02 | -0.04 | 0.00 | Upgrade |
EPS (Diluted) | -0.15 | -0.23 | 0.09 | 0.01 | -0.04 | 0.00 | Upgrade |
EPS Growth | - | - | 473.33% | - | - | -80.70% | Upgrade |
Free Cash Flow | -7.22 | -14.12 | 11 | 1.11 | 4.47 | 1.68 | Upgrade |
Free Cash Flow Per Share | -0.07 | -0.14 | 0.12 | 0.01 | 0.06 | 0.02 | Upgrade |
Gross Margin | 28.83% | 13.43% | 37.59% | 29.60% | 34.52% | 33.86% | Upgrade |
Operating Margin | -23.28% | -47.50% | 9.00% | 3.38% | 2.64% | -1.87% | Upgrade |
Profit Margin | -30.60% | -53.97% | 9.12% | 1.93% | -8.00% | 1.06% | Upgrade |
Free Cash Flow Margin | -15.43% | -34.76% | 12.18% | 1.57% | 11.30% | 5.64% | Upgrade |
EBITDA | -5.15 | -14.12 | 12.27 | 4.83 | 2.8 | 0.88 | Upgrade |
EBITDA Margin | -11.01% | -34.76% | 13.59% | 6.86% | 7.08% | 2.94% | Upgrade |
D&A For EBITDA | 5.74 | 5.18 | 4.15 | 2.45 | 1.75 | 1.43 | Upgrade |
EBIT | -10.89 | -19.3 | 8.12 | 2.38 | 1.05 | -0.56 | Upgrade |
EBIT Margin | -23.28% | -47.50% | 9.00% | 3.38% | 2.64% | -1.87% | Upgrade |
Updated Nov 12, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.